JNJ
Johnson & Johnson
NYSE · Healthcare · Drug Manufacturers - General · US
$275.15
−1.18%Jul 23, 2026, 13:58 UTC
Johnson & Johnson announced positive late-stage trial results for its combination treatment Tecvayli and Talvey for relapsed or refractory multiple myeloma, showing an 89% reduction in risk of disease progression or death.
Source:Jul 15, 2026, 16:09 UTC
Johnson & Johnson launched AI-powered imaging and mapping capabilities for electrophysiology.
Source:Jul 15, 2026, 16:09 UTC
Johnson & Johnson reported early momentum for a drug releasing system for bladder cancer treatment.
Source:Jul 8, 2026, 11:45 UTC
Johnson & Johnson announced that the U.S. FDA approved its Dual Energy THERMOCOOL SMARTTOUCH SF Platform.
Source:Jul 4, 2026, 07:51 UTC
Stayfree launched Stayfree Xpert XL, a new sanitary pad with a three-in-one protection system, to expand its menstrual hygiene portfolio.
Source:Jun 30, 2026, 00:00 UTC
Matthew Pauls was appointed as a Class I director of Palvella Therapeutics, Inc.
Jun 29, 2026, 16:40 UTC
J&J received a positive CHMP opinion for expanded use of Tecvayli in combination with Darzalex SC for relapsed/refractory multiple myeloma.
Source:Jun 25, 2026, 09:00 UTC
Johnson & Johnson made its Dual Energy THERMOCOOL SMARTTOUCH SF Platform available in Europe, advancing cardiac ablation technology.
Source:Jun 15, 2026, 10:00 UTC
Johnson & Johnson invested more than $1 billion to build a new distribution facility and expand manufacturing, packaging, and distribution capabilities for its Vision operations in Jacksonville, Florida.
Jun 14, 2026, 07:15 UTC
Legend Biotech announced first clinical proof-of-concept data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, in relapsed/refractory B-cell Non-Hodgkin Lymphoma.
Jun 11, 2026, 11:45 UTC
Johnson & Johnson expanded U.S. availability of its TECNIS PureSee IOL, an advanced lens option for cataract surgeons and patients.
Source:Jun 11, 2026, 06:03 UTC
Johnson & Johnson presented pivotal Phase 2/3 study results for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia at EHA 2026 in Stockholm.
Source:Jun 10, 2026, 15:22 UTC
A Los Angeles jury awarded $32 million to the family of Maria Lozano, finding Johnson & Johnson liable for her mesothelioma from asbestos-contaminated talc.
Source:Jun 8, 2026, 12:00 UTC
Johnson & Johnson has agreed to acquire Firefly Bio, Inc. for $1 billion in cash.
Jun 6, 2026, 01:56 UTC
A California jury reached a defense verdict in favor of Johnson & Johnson in the second bellwether ovarian cancer talcum powder trial in Los Angeles.
Jun 3, 2026, 04:04 UTC
Johnson & Johnson announced that nipocalimab met its primary endpoint in a Phase 2 study for systemic lupus erythematosus, with results presented at a conference.
Source:Jun 2, 2026, 10:30 UTC
LISTERINE introduced a new range of mouthwash intensities, including Extra Mild, available nationwide as of June 2, 2026.
Jun 1, 2026, 02:03 UTC
Legend Biotech held an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multiple myeloma.
Source:May 31, 2026, 13:00 UTC
Johnson & Johnson announced Phase 3 study results for ERLEADA (apalutamide) in prostate cancer, showing reduced risk of metastasis or death.
Source:May 31, 2026, 12:29 UTC
Johnson & Johnson announced pivotal results from the OrigAMI-4 study for RYBREVANT FASPRO in advanced head and neck cancer.
Source:
← PreviousPage 2